OpenAI unveils GPT-Rosalind

OpenAI has introduced a new artificial intelligence model, GPT-Rosalind, aimed at advancing research in life sciences, including biochemistry, drug discovery, and translational medicine. Named after pioneering scientist Rosalind Franklin, the model reflects the company’s growing focus on applying AI to complex scientific domains.  

GPT-Rosalind is designed to assist researchers in navigating vast scientific datasets, analysing the latest research papers, and generating insights for experimental planning. It enables users to query databases, integrate findings from multiple sources, and propose new hypotheses, helping streamline early-stage discovery processes.

Built on OpenAI’s latest internal models, GPT-Rosalind is being released as a research preview. It is accessible through ChatGPT, Codex, and OpenAI’s API for selected users under a controlled access framework. In parallel, the company has launched a free Life Sciences research plugin for Codex, which connects scientists to more than 50 specialised tools and data sources, further expanding the model’s practical applications.

OpenAI is collaborating with major industry players such as Amgen, Moderna, and Thermo Fisher Scientific to integrate GPT-Rosalind into real-world research workflows.

The launch comes amid increasing demand for AI-driven solutions in pharmaceutical and biotech research, where speed and accuracy are critical. Organisations are turning to advanced AI tools to accelerate drug development timelines and improve research efficiency.

Alongside this development, OpenAI has also introduced GPT-5.4-Cyber, a specialised version of its flagship model tailored for defensive cybersecurity applications. These launches signal the company’s broader strategy to deploy domain-specific AI models across high-impact industries, including healthcare and digital security.